Ariceum Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Phase 1
Recruiting
- Conditions
- Small Cell Lung Cancer Extensive StageMerkel Cell Carcinoma
- Interventions
- Drug: 225Ac-SSO110 + SoC
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Ariceum Therapeutics GmbH
- Target Recruit Count
- 50
- Registration Number
- NCT06939036
- Locations
- 🇺🇸
Biogenix Molecular, Miami, Florida, United States
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Not Applicable
Active, not recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Other: Data collection
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Ariceum Therapeutics GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT05017662
- Locations
- 🇦🇺
Peter Maccallum Cancer Center, Melbourne, Australia
🇦🇹Medical University of Vienna, Vienna, Austria
🇦🇺Ramsay Hollywood Private Hospital, Perth, Australia
© Copyright 2025. All Rights Reserved by MedPath